Brixen Kim T, Illum Niels O, Hansen Birgitte, Lund Allan Meldgaard, Mosekilde Leif
Odense Universitetshospital, Endokrinologisk Afdeling M, Odense C.
Ugeskr Laeger. 2007 Jan 1;169(1):30-4.
The molecular background for osteogenesis imperfecta (OI) is mutations in one of the two genes (COL1A1 and COL1A2) encoding collagen I. The disease is characterised by varying degrees of fragile bones, retarded growth, bone deformities, tooth abnormalities, blue sclerae, and hearing loss. Treatment with bisphosphonates reduces the incidence of fractures in children with severe OI, while this still remains to be demonstrated in adults. Results from bone marrow transplantation and animal experiments may lead to alternative treatment in severe OI.
成骨不全症(OI)的分子背景是编码I型胶原蛋白的两个基因(COL1A1和COL1A2)之一发生突变。该疾病的特征是骨骼脆弱程度不同、生长发育迟缓、骨骼畸形、牙齿异常、巩膜发蓝和听力丧失。双膦酸盐治疗可降低重度OI患儿的骨折发生率,而在成人中这一点仍有待证实。骨髓移植和动物实验的结果可能会为重度OI带来替代治疗方法。